Abstract
Importance Healthy HIV-positive insurance applicants have a similar risk of infection and produce a similar antibody response as HIV-negative applicants infected with COVID-19.
Objective Study the seroprevalence and immune response to COVID-19 in healthy HIV-positive life insurance applicants.
Design From January 2020 to March 2021, we examined the seroprevalence of COVID-19 in all HIV-positive applicants. Antibody level in 340 age and sex matched COVID-19 positive applicants, 170 HIV-positive and 170 HIV negative, are compared. The data was de-identified of all personal information and separated by month, age and sex.
Participants Self-reported healthy HIV positive life insurance applicants were tested for antibodies to COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was self-funded by Clinical Reference Laboratory, Lenexa, KS 66215
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants signed disclosures indicating that results may be used for research purposes. Western IRB (Puyallup, WA) reviewed the study under the Common Rule and applicable guidance and determined it is exempt under 45 CFR 46.104(d)(4) using de-identified study samples for epidemiologic investigation. WIRB Work Order #1-1324846-1.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact information: Robert L. Stout, PhD cell phone 913-488-5285
Data Availability
Data are available to non-commercial organizations for research use.
